Article Impact Level: HIGH Data Quality: STRONG Summary of New England Journal of Medicine, NEJMc2508629. https://doi.org/10.1056/NEJMc2508629 Dr. Adina F. Turcu et al.
Points
- Baxdrostat, a new aldosterone synthase inhibitor, caused an average blood pressure reduction of 25 mmHg in patients with primary aldosteronism, a clinically significant improvement.
- The SPARK Phase 2a trial involved 15 patients with uncontrolled hypertension who were monitored for 72 weeks while receiving escalating doses of the investigational drug.
- The treatment successfully suppressed aldosterone levels by an average of 90 percent and also corrected hypokalemia, a common metabolic abnormality associated with this condition.
- Some participants experienced sustained normalization of blood pressure and hormone levels after treatment, suggesting potential for a lasting cure previously limited to invasive procedures.
- Larger clinical trials are now underway to confirm these findings, with researchers anticipating potential regulatory approval for this new class of drugs within three years.
Summary
A phase 2a clinical trial (SPARK) evaluated the efficacy and safety of baxdrostat, a second-generation aldosterone synthase inhibitor, in patients with primary aldosteronism. The study, published in the New England Journal of Medicine, investigated 15 patients with confirmed primary aldosteronism and uncontrolled hypertension despite concurrent antihypertensive medications. The primary outcome revealed a significant therapeutic effect, with baxdrostat inducing an average fall in blood pressure of 25 mmHg. While confidence intervals and hazard ratios were not provided in the source text, this reduction is noted as being two to three times greater than that of typical monotherapy.
The open-label trial followed patients for 72 weeks, implementing a dose-escalation protocol for baxdrostat. The drug was reported to be well-tolerated at all but the maximum tested dose. In addition to blood pressure control, treatment resulted in a 90% average suppression of aldosterone levels and the normalization of potassium levels, thereby resolving the hypokalemia commonly associated with this condition. The study also noted that primary aldosteronism is estimated to be the cause of 1 in 10 cases of hypertension, yet fewer than 1 in 100 individuals with the condition are ever diagnosed.
Notably, some participants maintained normal blood pressure and hormone levels even after discontinuing the medication, suggesting a potential for durable remission, a benefit previously associated only with surgical or ablative therapies. Following these promising results, larger pivotal trials are now underway to confirm these findings. Researchers anticipate that the data from these larger studies could lead to regulatory approval for baxdrostat as a treatment for primary aldosteronism within the next two to three years, potentially changing the standard of care for this underdiagnosed disorder.
Link to the article: https://www.nejm.org/doi/10.1056/NEJMc2508629
References Turcu, A. F., Freeman, M. W., Bancos, I., Ben-Shlomo, A., Hamidi, O., Hamrahian, A. H., Huang, W., Kirschner, L. S., Sam, R., Mallappa, A., Tuyishimire, B., Lihn, A. S., Perl, S., & Brown, M. J. (2025). Phase 2a study of baxdrostat in primary aldosteronism. New England Journal of Medicine, NEJMc2508629. https://doi.org/10.1056/NEJMc2508629
